Morgan Stanley analyst Tejas Savant raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $16 from $11 and keeps an Equal Weight rating on the shares following the company’s recent Q3 report.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies’ Earnings Call Highlights Growth and Challenges
- Adaptive Biotechnologies price target raised to $20 from $17 at JPMorgan
- Adaptive Biotechnologies: Strong Q3 Performance and Favorable Conditions Drive Buy Rating
- Adaptive Biotechnologies Reports Strong Q3 2025 Growth
- Strong Q3 Performance and Market Position Drive Buy Rating for Adaptive Biotechnologies